The first 5 pages, shown as text so search engines and readers can find this document.
Page 1
Vol.:(0123456789)1 3Aging Clinical and Experimental Research (2022) 34:2603–2623
https://doi.org/10.1007/s40520-022-02279-6
REVIEW ARTICLE
Role of vitamin D supplementation in the management
of musculoskeletal diseases: update from an European Society
of Clinical and Economical Aspects of Osteoporosis, Osteoarthritis
and Musculoskeletal Diseases (ESCEO) working group
Thierry Chevalley1 · Maria Luisa Brandi2 · Kevin D. Cashman3 · Etienne Cavalier4 · Nicholas C. Harvey5,6 ·
Stefania Maggi7 · Cyrus Cooper5,6,8 · Nasser Al‑Daghri9 · Oliver Bock10,11 · Olivier Bruyère12 · Mario Miguel Rosa13 ·
Bernard Cortet14 · Alfonso J. Cruz‑Jentoft15 · Antonio Cherubini16 · Bess Dawson‑Hughes17 ·
Roger Fielding17 · Nicholas Fuggle5,6 · Philippe Halbout11 · John A. Kanis18,19 · Jean‑Marc Kaufman20 ·
Olivier Lamy21 · Andrea Laslop22 · Maria Concepción Prieto Yerro23 · Régis Radermecker24 ·
Jotheeswaran Amuthavalli Thiyagarajan25 · Thierry Thomas26 · Nicola Veronese27 · Marten de Wit28 ·
Jean‑Yves Reginster29 · René Rizzoli1
Received: 14 September 2022 / Accepted: 10 October 2022 / Published online: 26 October 2022
© The Author(s) 2022
Abstract
Vitamin D is a key component for optimal growth and for calcium–phosphate homeostasis. Skin photosynthesis is the main
source of vitamin D. Limited sun exposure and insufficient dietary vitamin D supply justify vitamin D supplementation
in certain age groups. In older adults, recommended doses for vitamin D supplementation vary between 200 and 2000 IU/
day, to achieve a goal of circulating 25-hydroxyvitamin D (calcifediol) of at least 50 nmol/L. The target level depends on
the population being supplemented, the assessed system, and the outcome. Several recent large randomized trials with oral
vitamin D regimens varying between 2000 and 100,000 IU/month and mostly conducted in vitamin D-replete and healthy
individuals have failed to detect any efficacy of these approaches for the prevention of fracture and falls. Considering the
well-recognized major musculoskeletal disorders associated with severe vitamin D deficiency and taking into account a
possible biphasic effects of vitamin D on fracture and fall risks, an European Society for Clinical and Economic Aspects
of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) working group convened, carefully reviewed, and
analyzed the meta-analyses of randomized controlled trials on the effects of vitamin D on fracture risk, falls or osteoarthritis,
and came to the conclusion that 1000 IU daily should be recommended in patients at increased risk of vitamin D deficiency.
The group also addressed the identification of patients possibly benefitting from a vitamin D loading dose to achieve early
25-hydroxyvitamin D therapeutic level or from calcifediol administration.
Keywords Vitamin D · Fragility fracture · Falls · Osteoarthritis
Introduction
Vitamin D plays a major role in optimal growth and in cal-
cium–phosphate homeostasis. In humans, skin photosynthe-
sis is the main endogenous source of vitamin D. When sun
exposure is limited and in case of insufficient vitamin D
dietary supply, vitamin D supplementation is recommended
particularly in certain age groups [1, 2]. A majority of guide-
lines consistently recommend 400 IU/day (10 μg) to prevent
rickets during the first year of life [3]. Calcium intake of
200 and 260 mg/day before 6 months and before 12 months,
respectively, is also advised [1]. For treatment of nutritional
rickets, the dose of 2000 IU/day for at least 3 months is rec-
ommended, with a normalization of PTH levels. Whilst rec-
ommendations for rickets prevention and treatment in child-
hood and adolescence are widely accepted [3], the target
for calcifediol (25-hydroxyvitamin D (25(OH)D)) levels is
still discordant among the various guidelines [2]. Regarding
* Thierry Chevalley
Thierry.chevalley@hcuge.ch
Extended author information available on the last page of the article
Page 2
2604 Aging Clinical and Experimental Research (2022) 34:2603–26231 3
the preventive effect of vitamin D on fracture, many meta-
analyses of RCTs have shown contradictory results, some
showing no effect at all, while others showed a beneficial
anti-fracture effect of vitamin D supplementation particu-
larly when combined with calcium [2, 4].
Although 50 nmol/L of serum of 25(OH)D is considered
as a threshold value for optimal bone health by many guide-
lines [3], higher concentrations, and correspondingly higher
intake of vitamin D, have been suggested by some experts
for maintaining bone health [5–8]. However, recent large
trials conducted in vitamin D-replete healthy subjects have
reported no effects either on falls [9, 10], non-vertebral frac-
tures [9, 11], bone health outcomes [10], chronic knee pain
[12], various clinical outcomes [13], and body composition
[14]. It should be noted that 70% of RCTs with clinical out-
comes were performed in patients with baseline 25(OH)D
above 40 nmol/L and out of twenty-five large RCTs only one
was undertaken in a vitamin D-deficient population (25(OH)
D below 25 or 30 nmol/L) and two in vitamin D-insufficient
populations (25(OH)D below 50 nmol/L) [15]. Indeed, vita-
min D deficiency has been shown to be a risk factor for vari-
ous musculoskeletal disorders, including fractures and falls
[16, 17]. To identify vitamin D regimens to correct vitamin
D deficiency and prevent related musculoskeletal events,
a European Society for Clinical and Economic Aspects of
Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
(ESCEO) working group reviewed and analyzed meta-anal-
yses of randomized controlled trials on the effects of vitamin
D supplementation on fracture risk, falls or osteoarthritis.
This paper, which updates the 2013 ESCEO recommenda-
tion paper [18], is a narrative review of the data used by the
working group to reach the conclusion that 1000 IU vitamin
D daily should be recommended in patients at increased risk
of vitamin D deficiency.
Methods
An ESCEO expert working group, comprising expert clini-
cians of different medical specialties (physical rehabilitation
medicine (PRM) specialists, laboratory medicine special-
ists, rheumatologists, endocrinologists and geriatricians)
and researchers was convened in May 2022, under the aus-
pices of the WHO Collaborating Center for Epidemiology
of Musculoskeletal Health and Aging (University of Liège,
Belgium). This group reviewed the literature and discussed
the current state of the art on the followings topics: (1) Epi-
demiology of vitamin D deficiency; (2) New perspectives in
the assessment of vitamin D circulating levels; (3) Vitamin
D and fracture prevention (effects in depleted and replete
populations); (4) Vitamin D and falls (effects in depleted
and replete populations); (5) Vitamin D and osteoarthritis
(effects in depleted and replete populations); (6) Metabolic
conditions justifying the use of 25(OH)D (calcifediol); and
(7) Vitamin D treatment safety and therapeutic window. This
paper reflects the presentations and the discussions of the
working group based on an extensive narrative literature
review focusing on the most robust evidence such as a series
of recent meta-analyses. After discussion and deliberation
amongst the experts regarding the quality, scope, and con-
text of the collected evidence, a first draft of the manuscript
was prepared. This draft manuscript was circulated to all the
members of the expert group for critical revision. Any addi-
tionally identified high-quality evidence was subsequently
incorporated. The first author coordinated the preparation
of the final version of the manuscript, which was circulated
to the entire expert group for final approval and unanimous
endorsement.
Epidemiology of vitamin D deficiency
Vitamin D deficiency varies depending on the thresholds
used for serum 25(OH)D values [19]. Furthermore, serum
25(OH)D levels vary over the course of the year in relation
to UVB exposure [20–22]. Low thresholds such as 25(OH)D
below 25 or 30 nmol/L (i.e., deficiency or severe deficiency,
depending on the experts society) have been suggested when
the focus was more on the prevention of rickets/osteomalacia
and a higher threshold below 50 nmol/L (insufficiency or
deficiency, depending on the experts society) was chosen if
the concern was suppression of PTH. Using a < 30 nmol/L
threshold, 5% of Americans and about 9% of Canadians
have serum values of 25(OH)D below this level [22, 23].
Regarding vitamin D status in the United States, an Ameri-
can survey between 2011 and 2014 suggested that, on aver-
age, 5% of the population was at risk of deficiency as defined
with 25(OH)D level below 30 nmol/L, but if the population
was divided according to the ethnicity, then the risk of vita-
min D deficiency of the Caucasian population was around
2% as compared to 17.5% of the black population [23]. In
Europe, 1 out of 8 inhabitants (13% on average) are at risk
of vitamin D deficiency (based on a 25(OH)D level below
30 nmol/L), but this percentage can increase up to 28–65%
for ethnic minority groups within Northern European coun-
tries [24]. However, the prevalence of serum 25(OH)D
below 30 nmol/L ranged from 4.6 to 30.7% and this range
increased from 27.2 to 61.4% for 25(OH)D using a threshold
of 50 nmol/L according to European standardized data [24].
Considering both continents, this represents 120 million of
subjects who are vitamin D deficient using a 30 nmol/L
threshold and 390 million of subjects with 25(OH)D below
50 nmol/L. Predictors for low 25(OH)D in all models were
higher age, higher BMI, use of walking aid, limited time
spent outdoors in Summer, smoking, no calcium supplemen-
tation, no use of multivitamins, no use of vitamin D on pre-
scription or self-administered, and the season when serum
Page 3
2605Aging Clinical and Experimental Research (2022) 34:2603–26231 3
25(OH)D was tested [25]. There are other potential factors
that contribute to increased risk of vitamin D deficiency such
as inflammation [5, 26, 27], patients with fat malabsorption
syndromes, bariatric surgery, nephrotic syndrome, as well
as patients on a variety of medications which may interfere
with vitamin D absorption or metabolism [5].
The major source of vitamin D in humans is ultravio-
let B (UVB)-induced dermal synthesis of cholecalciferol,
whereas food sources are believed to play a lesser role,
although among white residents of the UK, meat eaters have
20 nmol/L higher 25(OH)D than vegans [28]. There is a
clear trend of decreasing UVB exposure by moving from
South to North within Europe, with an almost six-fold dif-
ference in mean yearly modeled UVB dose between these
two latitudes from ~ 35○ to ~ 69○ N [29]. Significant differ-
ences in UVB availability between inland and coastal areas
were also reported at the same latitude within the UK, due
to different cloud conditions [30]. Environmental and per-
sonal factors influence cutaneous vitamin D synthesis [31]:
the main determinants are solar zenith angle, controlling
the potential available UVB (latitude, season and time of
day), skin type and age, clothing, sunscreen, and outdoor
activities. Therefore, UVB availability and diet, as well as
other lifestyle factors, must be considered in preventive and
therapeutic approaches to vitamin D deficiency. In Europe,
if the extreme North and South are excluded, dietary supply
becomes especially important 4–8 months a year when vita-
min D synthesis in the skin is very limited and 50–100% of
Europeans have vitamin D intakes below the recommended
level. Indeed, the vast majority of European countries con-
sume below the estimated average requirement of 10 ug/
day of vitamin D intake (400 IU) based on European dietary
surveys with a mean intake of 3.3 and 2.7 ug/day in adult
males and females, respectively [32]. The mean vitamin D
intake varies between 1.5 and 5 μg/day in Western Europe
and below 1 μg/day to about 3 μg/day in Southern Europe,
while in Northern Europe it ranges between 4 and 14 μg/
day [33]. According to WHO, the strategies for the control
of micronutrient malnutrition are to increase the diversity
of the foods consumed, food fortification and supplemen-
tation [34]. Nevertheless, increasing the diversity of foods
consumed and improving intake of naturally occurring vita-
min D-rich foods is particularly challenging because there
are very few food sources rich in vitamin D. For a serum
25(OH)D threshold of 25 nmol/L, a vitamin D intake range
of 7.5 and 10 μg/day would allow 95% and 97.5% of individ-
uals, respectively, to maintain their winter serum 25(OH)D
above this threshold. On the other hand, for a serum 25(OH)
D threshold of 50 nmol/L, the corresponding vitamin D
intakes needed are 23.5 and 25 ug/day (≈ 1000 IU/day),
respectively, intakes which are too difficult to reach with
food fortification and may need a more active public health
approach involving recommendations for lifestyle including
sunshine exposure, healthy nutrition, food fortification, and
vitamin D supplementation [35].
In summary, vitamin D deficiency (25(OH)D below 25 or
30 nmol/L) is evident throughout the European population at
prevalence rates that are of concern and that require action
both from a public health and a clinical perspective.
New perspectives in the assessment of vitamin D
circulating levels
Commonly cited indications where vitamin D testing is
appropriate are: rickets, osteomalacia, osteoporosis, hyper-
parathyroidism, malabsorption syndromes, medications
affecting absorption or metabolism of vitamin D (anti-
fungals, HIV antiretroviral therapy, anticonvulsants, etc.),
chronic kidney disease, hypophosphatemia and hypo/hyper-
calcemia, deeply pigmented skin, and isolated elevation of
alkaline phosphatase [36]. A major issue in the determina-
tion of a 25(OH)D threshold value is the absolute need for
a standardized method. In 2010, the Vitamin D External
Quality Assessment Scheme (DEQAS) for the determination
of 25(OH)D included 13 different methods which displayed
high coefficient of variation and a range of fourfold between
the lowest and highest values for a given sample. To stand-
ardize 25(OH)D measurement in both clinical and research
laboratories, the Vitamin D Standardization Program
(VDSP) was agreed in 2010 by the Office of Dietary Supple-
ments (ODS) of the National Institutes of Health (NIH) [37].
This collaboration involved the coordinated efforts of ODS,
the National Institute for Standards and Technology (NIST),
the Centers for Disease Control and Prevention (CDC), the
Vitamin D External Quality Assessment Scheme (DEQAS),
the College of American Pathologists (CAP), the Ameri-
can Association for Clinical Chemistry (AACC), the Inter-
national Federation of Clinical Chemistry and Laboratory
Medicine (IFCC), along with national surveys and collabora-
tors around the world. The VDSCP calibration-certification
process conducted by CDC comprised 2 phases: Phase 1
assessed and readjusted current calibration based on 40 sin-
gle donor samples with assigned target values. In Phase 2,
four quarterly challenges with 10 unknown serum samples
were performed to verify that calibration was stable over
1 year. If performance criteria of a mean bias ≤ ± 5% and an
imprecision ≤ 10% were reached, then the certified labs were
listed on the CDC website https://www.cdc.gov/labstandar
ds/pdf/hs/CDC_Certified_Vitamin_D_Procedures-508.pdf.
In 2018, the DEQAS reported an explosion of the number of
methods for 25(OH)D determination, but with lower coef-
ficient of variation values as compared to 2010 and a nar-
rowing distribution with a smaller range of twofold between
the lowest and highest values for a given sample. The impact
of the VDSP re-standardization was an overall improvement
in the bias observed between the reference method and the
Page 4
2606 Aging Clinical and Experimental Research (2022) 34:2603–26231 3
different commercially available assays. Liquid chromatog-
raphy–mass spectrometry (LCMS/MS) methods performed
globally better than immunoassays, but all LCMS/MS meth-
ods are not equivalent and there are still important issues
with immunoassays and LCMS/MS.
All the standardization process was performed with sam-
ples from healthy individuals, but 25(OH)D should also be
measured in patients with different diseases (CKD, osteo-
porosis, etc.), physiological status (pregnancy), or ethnicity.
Vitamin D binding protein concentration and polymorphism
have also an impact on the results. In addition serum matrix
may be different in sick patients and in healthy individuals
[38].
The vitamin D metabolite ratio (VMR) 24,25(OH)2D to
25(OH)D has been proposed as a new marker of vitamin D
status and as being predictive of fracture risk [39]. Cavalier
et al. suggested that in clinical practice the concentrations
of 24,25(OH)2D and 25(OH)D should be reported together
with the probability that a ratio value is found in healthy
subjects [40]. This information would allow one to escape
the concept of vitamin D deficiency solely on the basis of a
25(OH)D threshold [5, 41–43]. For example, amongst indi-
viduals with a 25(OH)D concentration above 52 nmol/L,
over 99% exhibit detectable amounts of 24,25(OH)2D and,
thus, are probably vitamin D sufficient [44]. This finding
supports the 50 nmol/L cut-off recommended by the IOF
[45]. However, the ratio 24,25(OH)2D to 25(OH)D can only
be measured after determination of both moieties by LCMS/
MS.
In summary, great improvements in 25(OH)D assays
standardization have been achieved in recent years. LCMS/
MS methods generally perform better than immunoassays,
but all LCMS/MS methods are not equivalent. 24,25(OH)2D
and VMR are promising tools to evaluate vitamin D defi-
ciency at the individual level, but are only available with
LCMS/MS.
Vitamin D and fracture risk
In a prospective observational study in 1662 community-
dwelling elderly men followed over a period of 4 years,
a U-shaped association was observed with an increased
risk of fracture in men with either 25(OH)D values below
36 nmol/L or above 75 nmol/L [46]. Whether vitamin D,
calcium or both supplements together are effective for the
primary prevention of fractures is still debated. The absence
or the demonstration of a beneficial anti-fracture effect is
linked not only to the vitamin D dose, addition or not of
calcium and duration of vitamin D supplementation but also
largely to the population studied and in particular if this
population is vitamin D deplete or replete.
In a Cochrane review [47], taking into account 11 studies
involving more than 27,000 patients, vitamin D alone did
not prevent hip fractures or any fractures (the latter based on
15 studies including more than 28,000 patients) (Table 1).
On the other hand, the combination of vitamin D and cal-
cium reduced the incidence of hip fractures by 16% based
on 9 studies in almost 50,000 patients and the risk of any
fractures by 5% taking into account 10 studies involving
nearly 50,000 patients. In addition, fracture risk reduction
was shown to be more important in institutionalized patients
both for hip and for any fractures [47]. Nevertheless, even
in institutionalized patients, the reduction of fracture inci-
dence seems to be dependent on baseline serum 25(OH)
D levels. Indeed, in 3,270 French institutionalized women
with a mean age of 85 years and a baseline serum 25(OH)
D of 35 nmol/L, a supplementation of 800 IU of vitamin D
and 1200 mg of calcium for 18 months reduced the inci-
dence of hip and of non-vertebral fractures [48]. In contrast,
in an English study among 3440 institutionalized men and
women with a mean age of 85 years, but with a baseline
25(OH)D above 54 nmol/L, a supplementation of 100,000
units of vitamin D every 4 months for 3 years did not show
a significant decrease in the incidence of fractures at the hip
or at other sites [49]. More recently the Do-Health study
involving 2157 elderly subjects with a baseline 25(OH)
D of 56 nmol/L, a daily supplementation of 2000 IU of
vitamin D for 3 years did not reduce the incidence of non-
vertebral fractures [13]. In the VITAL trial performed in
more than 25,000 vitamin D-replete subjects, there was no
anti-fracture effect of 2000 IU/day of vitamin D [11]. With
only 7 against 8 fractures in patients with 25(OH)D below
a not prespecified 30 nmol/L threshold, a conclusion as to
whether a response to supplementation is detectable in vita-
min D-deficient patients cannot be drawn.
In the ViDA trial in New Zealand, a monthly administra-
tion of 100,000 IU of vitamin D over about 3 years, after
a loading dose of 200,000 IU, did not prevent fractures
with even a non-significant trend for a higher fracture risk
observed among healthy volunteers aged between 50 and
84 years and with a baseline 25(OH)D of 63 nmol/L [9].
Furthermore, an increase in falls and fractures was also pre-
viously observed with an annual high bolus of 500,000 IU of
vitamin D in community-dwelling elderly Australian women
at high risk of fracture, but with a baseline 25(OH)D consid-
ered as sufficient at around 50 nmol/L [50].
Many meta-analyses including various numbers of tri-
als, hence of subjects, were recently published [47, 51–66]
(Table 1). In that of Bolland et al. [59], which included 81
studies but with only 6% of vitamin D-deficient subjects
at baseline, supplementation of vitamin D alone was not
associated with a reduction of the incidence of total and
hip fractures as well as of falls. Moreover this system-
atic review not only excluded trials combining vitamin
D and calcium but included studies either with low doses
of vitamin D or conversely high doses, especially bolus,
Page 5
2607Aging Clinical and Experimental Research (2022) 34:2603–26231 3
Table 1 Meta-analyses on vitamin D supplementation and fractures
Author, year, studies Intervention tested Target population and limitations Results for fractures
Bischoff-Ferrari et al. (2009) [51]
12 RCTs (non- vertebral fractures)
N = 42,279
8 RCTs (hip fractures)
N = 40,886
Vit D ± calcium
Vit D ≤ 400 IU/d in 3 trials whereas the other 9
RCTs had mean intakes of 482–770 IU/d
Mean age of 78 years, 89% women
Duration from 12 to 84 months
Pooled relative risk 0.86 (95% CI 0.77–0.96) for
prevention of non-vertebral fracture and 0.91
(95% CI 0.78–1.05) for hip fracture
Calcium 500–1200 mg/d in combination with vit
D in 7 RCTs
For the higher dose (> 400 IU), pooled RR 0.80
(95% CI 0.72–0.89); n = 33,265, 9 trials for
non-vertebral fractures and 0.82 (95% CI 0.69–
0.97); n = 31,872, 5 trials for hip fractures
Lai et al. (2010) [52]
7 RCTs
N = 12,762
Vit D alone 400–1100 IU/day in 6 RCTs
Vit D 800 IU + calcium 1000 mg/day in 1 RCT
RCT including a minimum of 100 participants
with at least one radiologically confirmed hip
fracture in each group
RR 1.13 (95% CI 0.98–1.29) for hip fractures
No significant variations found between results of
studies randomizing participants to:
< 800 IU/day 1.14 (95% CI 0.86–1.49) or
≥ 800 IU/day 1.12 (95% CI 0.96–1.32)
Bergman et al. (2010) [53]
8 RCTs
N = 12,658
Vit D ± calcium 4 RCTs on non-vertebral fracture, n = 3510
5 RCTs on hip fracture, n = 7473
Vit D3 + calcium compared to placebo:
OR 0.77 (95% CI 0.6–0.93) for non-vertebral
fracture and OR 0.70 (95% CI 0.53–0.90) for
hip fracture
Chung et al. (2011) [54]
16 RCTs
N = 19,878
Vit D (400–1370 IU/d) alone
5 RCTs—N = 14,583
Elderly men and women with follow-up ranging
from 7 months to 5 years
Pooled relative risk 1.03 [95% CI 0.84 to 1.26],
with high heterogeneity
Vit D (300–1000 IU/d) + calcium 500–
1200 mg/d
11 RCTs—N = 52,915
Pooled relative risk, 0.88 [95% CI 0.78–0.99],
with moderate heterogeneity
Significant risk reduction among institutional-
ized elderly persons (relative risk, 0.71 [95%
CI 0.57–0.89])
Murad et al. (2012) [55]
Network meta-analysis
Vit D ± calcium Median age, 64 years; 86% females and 88%
Caucasians; median follow-up, 24 months
OR 0.81 (95% CI 0.68–0.96) for hip fracture and
OR 0.94 (95% CI 0.84–1.02) for non-vertebral
fracture
Vit D and calcium given separately were ineffective
Avenell et al. (2014) [47]
31 RCTs
N = 36,282
Vit D alone
11 RCTs, N = 27 693
15 RCTs, N = 28 272
12/31 RCTs had participants with a mean or
median age of 80 years or over
RR 1.12 (95% CI 0.98–1.29) for hip fracture
RR 1.03 (95% CI 0.96–1.11) for any fracture
Vit D + calcium
9 RCTs, N = 49 853
10 RCTs, N = 49 976
Institutional (2 RCTs), N = 3853
Prevention of fractures in community, nursing
home or hospital inpatient populations
RR 0.84 (95% CI 0.74–0.96) for hip fracture
RR 0.95 (95% CI 0.90–0.99) for any fracture
RR 0.75 (95% CI 0.62, 0.92) and RR 0.85 (95% CI
0.74, 0.98) for hip and any fracture, respectively
in institutionalized-dwellingsubjects
Weaver et al. (2016) [56]
8 RCTs
N = 30,970
Vit D + calcium Mostly adults aged 65 + years
– Excluded studies that tested vit D without
calcium
– Included 40% of the literature that contributed
to current guidelines on vit D
15% reduction of total fractures (RR = 0.85; 95%
CI 0.73–0.98)
30% reduction of hip fractures (RR = 0.70; 95%
CI 0.56–0.87)